I hear you but we are not comparing apples with apples on the patient cohort here.
MSB are treating 100% of the sickest in their trials and looking for 70% success rate ideally.
This other treatment they are not treating just the 6% being hospitalized, they are treating the 100% who test positive for COVID with a 4.7% reduction in hospitalization on that whole 100% who they are treating. So then it comes down to - is it worth the cost to treat the 100% infected for a 4.7% improvement over doing nothing. That is the harsh reality of this one.
I say yes save everyone but governments won't in their cost benefit analysis.
I hear you but we are not comparing apples with apples on the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
-0.005(0.44%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.12 | $1.385M | 1.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 29118 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 21946 | 9 |
View Market Depth
| Last trade - 10.36am 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |